New Generation Sterilizable Arthroscopic Joint Shaver High Speed Gearmotor Joins Portescap’s Surgical Motor Solutions Portfolio

Portescap, a global provider of miniature motion solutions, is pleased to announce the launch of the B0614A4, the latest generation of the arthroscopic joint shaver gearmotor. As one of the most advanced solutions for arthroscopic joint shavers, the new motor design merges Portescap’s twenty-five years of surgical motor solutions expertise with innovative technical features, resulting in a highly reliable motion solution that does not compromise on power density, speed or autoclavability.

The Size 6 brushless DC slotted motor can withstand more than 1,000 medical dishwasher and autoclave cycles. The unique output shaft seal option prevents liquids from entering the motor, thereby increasing the device’s lifetime and reliability. This premium motor is available with two standard nominal voltages.

Designed to run up to 14,000 RPM, the B0614A4 can achieve 100% more speed as compared to the speed of the prior generation. At only 106 grams, the motor’s lightweight and ergonomic design facilitates easier product handling and decreases surgeon hand strain, resulting in increased productivity. This Size 6 motor features an integrated gearhead and hall sensors for speed control. As with all Portescap’s motion solutions, the B0614A4 is easily customizable, making it easy to integrate within many powered surgical devices.

SMS B0614A4 gearmotors are an ideal solution for high speed shaver applications, specifically arthroscopic and small bone shavers. This makes the motor particularly well-suited for use in powered surgical hand tools used in minimally invasive surgical procedures to repair joints, including the hip, knee, and shoulder.

Image Caption: New Generation Sterilizable Arthroscopic Joint Shaver High Speed Gearmotor Joins Portescap’s Surgical Motor Solutions Portfolio

Read more Portescap articles on the DMA News Portal

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”